Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
200 participants
INTERVENTIONAL
2018-05-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Duration of Doxycycline Treatment in EM Patients
NCT03153267
Inflammatory Mediators in Erythema Migrans
NCT03956212
Antibiotic Treatment of Multiple Erythema Migrans
NCT01163994
Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans
NCT03584919
Duration of Antibiotic Treatment of Erythema Migrans
NCT00910715
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEM-7 days doxycycline
Doxycycline 100 milligram Oral Tablet bid, 7 days
Patients will receive doxycycline for 7 days.
MEM-14 days doxycycline
Doxycycline 100 milligram Oral Tablet bid, 14 days
Patients will receive doxycycline for 14 days.
Controls
Controls without a history of lyme disease.
No intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline 100 milligram Oral Tablet bid, 7 days
Patients will receive doxycycline for 7 days.
Doxycycline 100 milligram Oral Tablet bid, 14 days
Patients will receive doxycycline for 14 days.
Controls without a history of lyme disease.
No intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* immunocompromised
* serious adverse event to doxycycline
* taking antibiotic with antiborrelial activity within 10 days
* extracutaneous manifestations of lyme borreliosis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daša Stupica
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daša Stupica, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University Medical Centre Ljubljana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical center Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEM-Doxy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.